Randomised Evaluation of COVID-19 Therapy
Key facts
- Who runs it
- University of Oxford
- Where
- Belgium, Estonia, France, Ghana, India, Indonesia, Italy, Nepal, Netherlands, Portugal, Romania, South Africa, Spain, Sweden, United Kingdom, and Vietnam74 sites in 16 countriesChoose a country to see its sites
- Trial code
- NCT04381936
- EU 2023-507441-29-00
- EudraCT 2020-001113-21
- ISRCTN50189673
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 70,000 people, planned
- Started
- 19 Mar 2020
- Expected to end
- 30 Sept 2038
- Type of study
- Interventional, 23 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Lopinavir-Ritonavir
- Corticosteroid
- Hydroxychloroquine
- Azithromycin
- Convalescent plasma
- Tocilizumab
- Immunoglobulin
- Synthetic neutralising antibodies
- Aspirin
- Colchicine
- Baricitinib
- Anakinra
- Dimethyl fumarate
- High Dose Corticosteroid
- Empagliflozin
- Sotrovimab
- Molnupiravir
- Paxlovid
- Baloxavir Marboxil
- Oseltamivir
- Corticosteroids (dexamethasone)
- Record updated
- 21 April 2026
Who can take part
- Age
- 0 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Other criteria
- Eligibility Criteria (as per Protocol v28.0):
- Patients are eligible for the study if all of the following are true:
- (i) Hospitalised
- (ii) Pneumonia syndrome
- In general, pneumonia should be suspected when a patient presents with:
- typical symptoms of a new respiratory tract infection (e.g. influenza-like illness with fever and muscle pain, or respiratory illness with cough and shortness of breath); and
- objective evidence of acute lung disease (e.g. consolidation or ground-glass shadowing on X-ray or CT, hypoxia, or compatible clinical examination); and
- alternative causes have been considered unlikely or excluded (e.g. heart failure); However, the diagnosis remains a clinical one based on the opinion of the managing doctor (the above criteria are just a guide); (iii) One of the following diagnoses:
- Confirmed influenza A or B infection (including patients with SARS-CoV-2 co-infection)
- Community-acquired pneumonia (CAP) with planned antibiotic treatment (excluding patients with suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis or Pneumocystis jirovecii pneumonia); (iv) No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial; Patients with suspected or confirmed active pulmonary tuberculosis or Pneumocystis jirovecii pneumonia (also known as PCP or PJP) are excluded from the CAP comparison, as these infections are caused by specific organisms with distinct pathologies, and so are not usually categorised as CAP. Eligibility for the CAP comparison also requires planned antibiotic treatment, so patients being treated solely for fungal or viral pneumonia are not eligible; Patients with SARS-CoV-2 and influenza co-infection are eligible, but would be excluded from certain comparisons if the attending clinician believes that there is a specific contra-indication to one of the active drug treatment arms (see Protocol Appendix 2, Appendix 3 for children, and Appendix 4 for pregnant and breastfeeding women), or that the patient should definitely be receiving one of the active drug treatment arms then that arm will not be available for randomisation for that patient. For patients who lack capacity, an advanced directive or behaviour that clearly indicates that they would not wish to participate in the trial would be considered sufficient reason to exclude them from the trial; Patients who have been previously recruited into RECOVERY are eligible to be recruited again as long as their previous randomisation was >6 months ago. Patients will not be recruited into the same randomised comparison (e.g. sotrovimab vs. usual care) on more than one occasion, regardless of how far apart they occur; In some locations, children (aged <18 years) will not be recruited, to comply with local and national regulatory approvals (see Appendix 6); Note: the eligibility criteria has changed from COVID-19 to pneumonia (Influenza \& CAP). For detailed information about previous eligibility criteria please see the previous Protocol's on the study website: https://www.recoverytrial.net/uk/for-site-staff/site-set-up-1/regulatory-documents
This trial has no sites in United States.
It has sites in 16 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia.
Read full original descriptionShow less
The treatments being investigated are:
COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Casirivimab+Imdevimab, Tocilizumab, Aspirin, Baricitinib, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid or Anakinra (children only)
Influenza: Baloxavir marboxil, Oseltamivir, Corticosteroids (dexamethasone)
Community-acquired pneumonia: Corticosteroids (dexamethasone)
The 23 groups in the trial
- Standard CareNo study treatment, for comparison
Patient receives usual hospital care
- CorticosteroidsExisting treatment, for comparison
First (main) randomisation part A (COVID-19) \[This arm is now closed to recruitment\]
Treatment: Corticosteroid
- HydroxychloroquineExisting treatment, for comparison
First (main) randomisation part A (COVID-19) \[This arm is now closed to recruitment\]
- Lopinavir-RitonavirExisting treatment, for comparison
First (main) randomisation part A (COVID-19) \[This arm is now closed to recruitment\]
- AzithromycinExisting treatment, for comparison
First (main) randomisation part A (COVID-19) \[This arm is now closed to recruitment\]
- Convalescent plasmaExisting treatment, for comparison
First (main) randomisation part B (COVID-19) \[This arm is now closed to recruitment\]
- TocilizumabExisting treatment, for comparison
Participants with progressive COVID-19 (as evidenced by hypoxia and an inflammatory state) may undergo randomisation between Tocilizumab and no additional treatment. (Children with COVID-19 pneumonia are not eligible for this comparison). \[This arm is now closed to recruitment\]
- Intravenous ImmunoglobulinExisting treatment, for comparison
First (main) randomisation part A (children only) \[This arm is now closed to recruitment\]
Treatment: Immunoglobulin
- Synthetic neutralising antibodiesExisting treatment, for comparison
First (main) randomisation part B (COVID-19) \[This arm is now closed to recruitment\]
- AspirinExisting treatment, for comparison
First (main) randomisation part C (COVID-19) \[This arm is now closed to recruitment\]
- ColchicineExisting treatment, for comparison
First (main) randomisation part A (COVID-19) \[This arm is now closed to recruitment\]
- BaricitinibExisting treatment, for comparison
First (main) randomisation part D (COVID-19) \[This arm is now closed to recruitment\]
- AnakinraExisting treatment, for comparison
Randomisation for children only with PIMS-TS (Children with COVID-19 pneumonia are not eligible for this comparison). \[This arm is now closed to recruitment\]
- Dimethyl fumarateExisting treatment, for comparison
First (main) randomisation part A (COVID-19) (UK adults only; early phase assessment) \[This arm is now closed to recruitment\]
- High Dose CorticosteroidsExisting treatment, for comparison
First (main) randomisation part E (COVID-19) \[This arm is now closed to recruitment\]
Treatment: High Dose Corticosteroid
- EmpagliflozinExisting treatment, for comparison
First (main) randomisation part F (COVID-19) \[This arm is now closed to recruitment\]
- SotrovimabExisting treatment, for comparison
First (main) randomisation part J (COVID-19) \[This arm is now closed to recruitment\]
- MolnupiravirExisting treatment, for comparison
First (main) randomisation part K (COVID-19) \[This arm is now closed to recruitment\]
- PaxlovidExisting treatment, for comparison
First (main) randomisation part L (COVID-19) \[This arm is now closed to recruitment\]
- Baloxavir marboxilExisting treatment, for comparison
Randomisation part G (influenza)
- OseltamivirExisting treatment, for comparison
Randomisation part H (influenza)
- Corticosteroids (dexamethasone) (influenza arm)Existing treatment, for comparison
Randomisation part I (influenza)
Treatment: Corticosteroids (dexamethasone)
- Corticosteroids (dexamethasone) (community-acquired pneumonia arm)Existing treatment, for comparison
Randomisation part M (community-acquired pneumonia)
Treatment: Corticosteroids (dexamethasone)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Publications
- Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.The Lancet. Infectious diseases, 2026
- Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.The Lancet. Infectious diseases, 2025
- Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.Trials, 2024
- Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.Nature communications, 2024
- Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.The Lancet. Child & adolescent health, 2024
- Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.The lancet. Diabetes & endocrinology, 2023
- Antiplatelet agents for the treatment of adults with COVID-19.The Cochrane database of systematic reviews, 2023
- Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews, 2023
- Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.Lancet (London, England), 2023
- Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews, 2023
- Record updated
- 21 April 2026